

Amendment

The following listing of claims will replace all prior versions and listings of claims in the application.

Listing of the Claims:


1-12. (Canceled)

13. (Currently Amended) A vaccine for preventing viral-infections with influenza virus comprising:

an influenza virus antigen;

a peptide (Peptide A) comprising a sequence  $R_1\text{-XZXZ}_N\text{XZX-R}_2$ , whereby N is a whole number between 3 and 7, X is a positively charged natural and/or non-natural amino acid residue, Z is an amino acid residue selected from the group consisting of L, V, I, F and/or W, and  $R_1$  and  $R_2$  are independently -H,  $-\text{NH}_2$ ,  $-\text{COCH}_3$ , -COH, a peptide with up to 20 amino acid residues or a peptide reactive group or a peptide linker with or without a peptide;  $\text{X-R}_2$  is an amide, ester or thioester of the C-terminal amino acid residue of the peptide; and

an immunostimulatory oligodeoxynucleic acid molecule (I-/U-ODN) having the structure according to the formula (I):



wherein:

R1 is selected from hypoxanthine and uracile;

any X is O or S;

any NMP is a 2' deoxynucleoside monophosphate or monothiophosphate, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine-monophosphate or -monothiophosphate;

NUC is a 2' deoxynucleoside, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyinosine-, deoxythymidine-, 2-methyl-deoxyuridine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine;

a and b are integers from 0 to 100 with the proviso that a + b is between 4 and 150; and

B and E are common groups for 5' or 3' ends of nucleic acid molecules.

14. (Previously Presented) The vaccine of claim 13, wherein N is 5.

15. (Previously Presented) The vaccine of claim 13, further comprising an Al(OH)<sub>3</sub> adjuvant.

16-17. (Canceled)

18. (Currently Amended) The vaccine of claim [[18]]13, wherein the ~~viral antigen is an~~ influenza antigen further defined as is a haemagglutinin antigen or a neuraminidase antigen.

19. (Previously Presented) The vaccine of claim 13, further comprising a polycationic peptide.

20. (Currently Amended) The vaccine of claim 13, wherein Peptide A is KLKL<sub>5</sub>KLK (SEQ ID NO:6) and the I/U-ODN is oligo d(IC)<sub>13</sub>.

21. (Previously Presented) The vaccine of claim 13, further comprising an oligodeoxynucleotide containing a CpG-motif.

22. (Previously Presented) The vaccine of claim 13, further comprising a polycationic peptide and an oligodeoxynucleotide containing a CpG-motif.

23.-28. (Canceled)